Mar 06, 2008 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has earned a milestone payment from Myriad Genetics, Inc., for progress due to patient dosing in a Phase II trial being conducted by Myriad for Azixa(TM) (MPC-6827) in melanoma that has spread to the brain. Azixa is an apoptosis inducer with vascular disrupting activity licensed as part of a series of compounds by EpiCept to Myriad as part of an exclusive, worldwide development and commercialization agreement. The milestone payment is in conjunction with progress made in a Phase II trial of Azixa in patients with melanoma. Myriad had previously announced the initiation of two additional Phase II trials for Azixa in patients with non-small-cell lung cancer that has spread to the brain and glioblastoma multiforme brain cancer...
...Myriad has completed two Phase 1 clinical trials of Azixa in a total of 66 patients, one in patients with advanced or metastatic cancers and the other in patients with known brain metastases. In Phase I data previously reported by Myriad, Azixa appeared to have a biological effect on patients' cancers from many different primary tumors, including non-small-cell lung cancer, which is consistent with the mechanism of the drug candidate.... EpiCept's Press Release -
